Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionChimeric Antigen Receptors Modified T-Cells for Cancer TherapyNovel immunotherapies in lymphoid malignanciesCARs in chronic lymphocytic leukemia -- ready to driveFrom monoclonal antibodies to chimeric antigen receptors for the treatment of human malignanciesDeveloping strategies in the immunotherapy of leukemiasAdoptive T-cell therapy for LeukemiaUsing gene therapy to manipulate the immune system in the fight against B-cell leukemias4-1BB Agonists: Multi-Potent Potentiators of Tumor ImmunityChimeric antigen receptor therapy for cancerCD133, Selectively Targeting the Root of CancerCD137 and CD137L signals are main drivers of type 1, cell-mediated immune responsesCAR therapy: the CD19 paradigmCD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to DateAre BiTEs the "missing link" in cancer therapy?Designing chimeric antigen receptors to effectively and safely target tumorsCD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemiaB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsDifferentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenograftsFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceImmunotherapy in acute leukemiaChimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignanciesBiology and clinical application of CAR T cells for B cell malignanciesGene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cellsThe future is now: chimeric antigen receptors as new targeted therapies for childhood cancerSuccessful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor.Adoptive cell transfer as personalized immunotherapy for human cancer.In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.Immunotherapy of human cancers using gene modified T lymphocytes.Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors.Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosisInvariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.Genetically engineered T cells for the treatment of cancer.
P2860
Q26745600-6C0DD1A3-3332-43C4-982D-4EC93C550D50Q26773309-A51DBDAF-2C59-4EFA-9821-BB6766DED2CCQ26777394-34A4EED1-FA43-47C2-9770-D3C45FD0B9CBQ26830526-DB89F270-FE9B-4107-BC55-02CCF5F4D314Q26852919-0FB4259D-6B3F-4DEB-86D4-87469A101BB8Q26996310-A6EF1FED-FF65-45DB-BF26-FC2D28B26C91Q27006934-68BE4401-278E-4D5C-A1B1-78295DB4146BQ27011297-9CEBB543-886A-431E-9753-177E5196726EQ27012963-7E919566-25DC-40D3-96B8-CA225CBBBADEQ27013599-28580884-A3AD-4AC1-974E-B1443B0B8FCAQ28066353-FC7E6E76-DD61-412D-B740-823485265E39Q28072933-977EB407-FE75-4EEE-ADB5-7C638D6C21FDQ28081642-28B617B3-AF47-4932-8432-2D78D8996302Q28083296-686611F3-5BEC-4977-AA96-A177B77CD7E0Q28083907-AD626573-3151-4210-99FC-EAFE58661FDFQ28088526-DCFF85F7-CC00-481B-8D86-785623F55A1BQ29620607-FCB5823A-7C67-468B-925F-43F95BA148F2Q29620717-6078C145-1E26-43EC-9912-647DC38A2220Q30479628-1B3AEF0B-4904-4A0B-AC3B-4B2380BD49B0Q30827633-CD399DB8-9CCA-4805-9FE2-AB34C84C1A3CQ33606096-011594E7-36B3-4835-9E08-0008F5ED1436Q33607015-9C6E2A2F-CE6A-4C5F-B314-C706C2A47242Q33731552-37D39AD6-2A12-4210-9821-926746CC28FCQ33791998-262FF1C1-155D-4EEA-836E-84E43DD83169Q33819935-AFCB31A2-D7E2-43D8-9FA2-FC1F490B5D07Q33907565-1DAF8502-0F1D-4A4C-B275-FF7414E97FFEQ33913839-81921B49-EC91-402D-954E-9FC857A6E623Q33992425-4F73C884-9604-43A6-B836-E0131134ED28Q33993529-FB206645-8B37-492E-81FA-1A6FF7DC6396Q34007762-DF89FB03-FECD-44FA-ACCF-C80C4A37CE55Q34042430-9A85D3F2-D16F-4DCE-8C52-A41EC2C2B234Q34043643-20E18DD9-7019-422F-A673-2EF1DD15F004Q34073529-F5965328-5F95-4E18-88D7-4330F7D30702Q34122292-72A8B2E8-51D1-4418-BDA9-DF3AA4244B96Q34153598-A3647BDD-77D0-4D78-8513-15BE0E155BF5Q34188383-025A129F-1801-4C04-8827-A169288F967BQ34205181-36B215AC-28AA-4267-B88E-D556236C850DQ34338159-83D0B91E-E95F-4731-B9B8-5573F7BCEBEBQ34431441-B8B889D9-DE79-4B3D-9537-FE81A5112053Q34645898-64DE897A-57B2-428E-B6FD-1CFBAC03217D
P2860
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Chimeric receptors with 4-1BB ...... acute lymphoblastic leukemia.
@en
type
label
Chimeric receptors with 4-1BB ...... acute lymphoblastic leukemia.
@en
prefLabel
Chimeric receptors with 4-1BB ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1433
P1476
Chimeric receptors with 4-1BB ...... t acute lymphoblastic leukemia
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403302
P577
2004-04-01T00:00:00Z
P5875
P6179
1004538568